Clinical Trials on Venous Thrombosis Upper Extremity Superficial Veins in Hungary

Total 24 results

Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Daiichi Sankyo, Inc.

Completed

Cancer Venous Thromboembolism (VTE)

Cancer | Venous Thromboembolism (VTE) | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

United States, Netherlands, Italy, Belgium, France, Hungary
University of Pecs
University of Debrecen

Unknown

Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion (BRAVO)

Macular Edema | Retinal Vein Occlusion

Hungary
Daiichi Sankyo, Inc.

Completed

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Pulmonary Embolism | Venous Thromboembolism (VTE) | Deep Vein Thrombosis (DVT)

United States, Israel, Spain, Czechia, Singapore, Canada, Argentina, Brazil, Bulgaria, Chile, Croatia, Denmark, El Salvador, France, Germany, Guatemala, Hungary, India, Kenya, Korea, Republic of, Lebanon, Malaysia, Netherlands, Norway, ... and more
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Venous Thrombosis | Deep Vein Thrombosis

Italy, Austria, Brazil, Hungary, Netherlands, South Africa, Israel, Australia, Germany
Daiichi Sankyo, Inc.

Completed

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Venous Thrombosis | Thromboembolism | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

France, United States, Japan, Denmark, Italy, Russian Federation, Czechia, Germany, India, Israel, Philippines, Taiwan, Ukraine, Australia, Austria, China, Argentina, Belarus, Belgium, Brazil, Canada, Chile, Estonia, Hungary, Korea, Republic... and more
Bayer

Completed

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

Venous Thrombosis | Deep Vein Thrombosis

Belgium, Israel, Italy, Spain, Switzerland, Colombia, New Zealand, Hungary, Canada, Sweden, Austria, Czechia, Germany, Poland, Netherlands, Peru, South Africa, Australia, Brazil
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (BRIGHTER)

Branch Retinal Vein Occlusion

Greece, Hungary, Australia, Spain, United Kingdom, Italy, Netherlands, Ireland, Portugal, France, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Bayer
Regeneron Pharmaceuticals

Completed

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (GALILEO)

Retinal Vein Occlusion

Italy, Korea, Republic of, France, Germany, Australia, Austria, Singapore, Hungary, Latvia, Japan
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Bristol-Myers Squibb

Completed

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Deep Vein Thrombosis | Pulmonary Embolism

United States, Argentina, Brazil, Mexico, Russian Federation, Australia, Canada, Hungary, Israel, Turkey, Denmark, Poland, Sweden
Bristol-Myers Squibb

Completed

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery (ADVANCE-2)

Deep Vein Thrombosis | Pulmonary Embolism

Italy, Korea, Republic of, China, Spain, South Africa, Colombia, Austria, France, Germany, Israel, Russian Federation, Denmark, Belgium, Singapore, Brazil, Mexico, Norway, Philippines, Poland, Ukraine, India, Malaysia, Hungary, Chile, Czech... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Bristol-Myers Squibb

Completed

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

Deep Vein Thrombosis | Pulmonary Embolism

Australia, Mexico, United Kingdom, United States, China, Spain, Denmark, France, Hungary, Israel, Russian Federation, Canada, Belgium, Argentina, Norway, Poland, Ukraine, India, Germany, Romania, Sweden
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO) (COMRADE-C)

Central Retinal Vein Occlusion | Macular Edema | Visual Impairment

Germany, United Kingdom, Hungary, Poland
Clearside Biomedical, Inc.

Terminated

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO (SAPPHIRE)

Macular Edema | Retinal Vein Occlusion

Spain, United States, Taiwan, Canada, Hungary, Israel, Portugal, Australia, Poland, United Kingdom, Austria, Denmark, India, Italy, Philippines, Slovakia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) (COMRADE-B)

Macular Edema | Visual Impairment | Branch Retinal Vein Occlusion

Germany, United Kingdom, Hungary, Poland, Czech Republic
Clearside Biomedical, Inc.

Terminated

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (TOPAZ)

Macular Edema | Retinal Vein Occlusion

United States, India, Australia, Hungary, New Zealand
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRYSTAL)

Central Retinal Vein Occlusion | Macular Edema

Greece, Hungary, Turkey, Australia, Austria, Netherlands, United Kingdom, Italy, Spain, Ireland, Portugal, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Kodiak Sciences Inc

Completed

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (BEACON)

Macular Edema | Retinal Vein Occlusion

Spain, United States, Latvia, Israel, France, Italy, Hungary, Germany, Poland, Slovakia, Puerto Rico, Czechia
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more

Clinical Trials on Venous Thrombosis Upper Extremity Superficial Veins in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations